Photo: depositphotos.com
May 12, 2025, 17:44
Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC
Elsevier Oncology shared a post on LinkedIn:
“Advancing NSCLC Treatment: Neoadjuvant and Adjuvant Osimertinib (NORA Study)
Lee et al. present groundbreaking findings on the use of Osimertinib in Stage IA to IIIA, EGFR-mutant non-small cell lung cancer (NSCLC).
Featured as the May Editor’s Choice article in the Journal of Thoracic Oncology, the NORA trial explores both neoadjuvant and adjuvant settings, offering new hope for improved patient outcomes.”
Title: Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC (NORA)
Authors: Jii Bum Lee, Su-Jin Choi, Hyo Sup Shim, Byung Jo Park, Chang Young Lee, Sumedha Sudhaman, Sharlene Velichko, Min Hee Hong, Byoung Chul Cho, Sun Min Lim.
You can read the Full Article in the Journal of Thoracic Oncology.
Vun-Sin Lim, Managing Editor of the Journal of Thoracic Oncology, shared this post, adding:
“Thanks Elsevier Oncology for featuring this JTO Editor’s Choice article of the May issue!
Also read the accompanying editorial by Drs Park and Saw.”
More posts featuring Osimertinib.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 11, 2025, 20:42
Jul 11, 2025, 20:37
Jul 11, 2025, 20:13
Jul 11, 2025, 19:32
Jul 11, 2025, 19:23
Jul 11, 2025, 19:07
Jul 11, 2025, 18:04